Xiuhua Wu

The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer

Jian Liu, Mingzhu Huang, Jie Cai, 2007, Cancer Chemotherapy and Pharmacology.

Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion

Jun Lee, Hui-jun Zhou, Xiuhua Wu, 2006, Anti-cancer drugs.

Apoptosis of human umbilical vein endothelial cells induced by artesunate.

Hui-jun Zhou, Guo-dong Wu, Xiuhua Wu, 2004, Vascular pharmacology.

Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation

Jun Lee, Jun Zhou, Guobing Zhang, 2012, Journal of Cancer Research and Clinical Oncology.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Jun Lee, Guobing Zhang, Xing-guo Zhang, 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells

Jun Lee, Hui-jun Zhou, Xiuhua Wu, 2005, Cancer Chemotherapy and Pharmacology.

Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer

N. Xu, Xiuhua Wu, Lin Run Wang, 2007, Cancer Chemotherapy and Pharmacology.

Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity

Wei Hu, Hui-jun Zhou, Xiuhua Wu, 2012, FEBS open bio.